Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancer

CONCLUSION: Pts with ROC reported high SB prior to starting palliative chemotherapy, similar among PRR-ROC and PPS-ROC≥3. High SB was strongly associated with early progression and death. SB should be actively managed and used to stratify patients in clinical trials. Clinical trials should measure and report symptom burden and the impact of treatment on symptom control.PMID:38412736 | DOI:10.1016/j.ygyno.2024.02.025

Source: Cancer Control - February 27, 2024 Category: Cancer & Oncology Authors: Felicia Roncolato Madeleine T King Rachel L O'Connell Yeh Chen Lee Florence Joly Felix Hilpert Anne Lanceley Yoshio Yoshida Jane Bryce Paul Donnellan Amit Oza Elisabeth Avall-Lundqvist Jonathan S Berek Jonathan A Ledermann Dominique Berton Jalid Sehouli M Source Type: research